^
    21d
    A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, National Cancer Center, China
    New P1 trial • Combination therapy • Metastases
    |
    Tagrisso (osimertinib) • BPI-1178
    7ms
    A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer (clinicaltrials.gov)
    P1/2, N=224, Recruiting, Beta Pharma (Suzhou) Co., Ltd. | N=122 --> 224 | Trial primary completion date: Jun 2023 --> Mar 2024
    Enrollment change • Trial primary completion date • Combination therapy • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    fulvestrant • letrozole • BPI-1178
    over2years
    A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer (clinicaltrials.gov)
    P1/2, N=122, Recruiting, Beta Pharma (Suzhou) Co., Ltd. | Trial primary completion date: Sep 2022 --> Jun 2023
    Clinical • Trial primary completion date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    fulvestrant • letrozole • BPI-1178
    almost4years
    A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer (clinicaltrials.gov)
    P1/2, N=100, Recruiting, Beta Pharma (Suzhou) Co., Ltd. | Not yet recruiting --> Recruiting | Initiation date: Mar 2020 --> Jun 2020
    Clinical • Enrollment open • Trial initiation date • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    fulvestrant • letrozole • BPI-1178
    4years
    A Study of BPI-1178 in Patients With Advanced Solid Tumor and HR+/HER2- Breast Cancer (clinicaltrials.gov)
    P1/2, N=100, Not yet recruiting, Beta Pharma (Suzhou) Co., Ltd.
    Clinical • New P1/2 trial • Combination therapy
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    fulvestrant • letrozole • BPI-1178